10 results on '"Kwak, Larry W."'
Search Results
2. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.
- Author
-
Samaniego, Felipe, Hagemeister, Fredrick, Romaguera, Jorge E., Fanale, Michelle A., Pro, Barbara, McLaughlin, Peter, Rodriguez, M. Alma, Neelapu, Sattva S., Fayad, Luis, Younes, Anas, Feng, Lei, Berkova, Zuzana, Khashab, Tamer, Sehgal, Lalit, Vega‐Vasquez, Francisco, and Kwak, Larry W.
- Subjects
CYCLOPHOSPHAMIDE ,RITUXIMAB ,B cell lymphoma ,LYMPHOMA treatment ,PROGRESSION-free survival ,TUMOR treatment - Abstract
We conducted a prospective phase II trial of pentostatin, cyclophosphamide and rituximab as initial therapy for patients with previously untreated advanced stage low-grade or indolent B-cell lymphomas ( iNHLs). Of 83 evaluable patients, 91·6% attained an overall response and 86·8% a complete or unconfirmed complete response. The 3-year progression-free survival ( PFS) and overall survival rates were 73% and 93%, respectively. The 3-year PFS rate was significantly different for different diagnoses ( P = 0·01): 83% [95% confidence interval ( CI): 0·72, 0·96] for follicular lymphomas, 73% (95% CI: 0·54, 1·0) for marginal zone lymphomas and 61% (95% CI: 0·46, 0·81) for small lymphocytic lymphomas. The most common adverse events were haematological. Of 509 cycles of chemotherapy administered, grade 3 or 4 neutropenia was reported in 68 cycles (13% of cycles administered) and most frequently occurred during cycles 4-6. This is the first report demonstrating the effectiveness of pentostatin, cyclophosphamide and rituximab in patients with previously untreated iNHLs, including those over 60 years of age. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
3. 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease.
- Author
-
Samaniego, Felipe, Berkova, Zuzana, Romaguera, Jorge E., Fowler, Nathan, Fanale, Michelle A., Pro, Barbara, Shah, Jatin J., McLaughlin, Peter, Sehgal, Lalit, Selvaraj, Vijairam, Braun, Frank K., Mathur, Rohit, Feng, Lei, Neelapu, Sattva S., and Kwak, Larry W.
- Subjects
LYMPHOMA treatment ,B cell lymphoma ,CANCER radioimmunotherapy ,YTTRIUM ,CD20 antigen ,THERAPEUTIC use of monoclonal antibodies ,NEUTROPENIA ,THERAPEUTICS ,TUMOR treatment - Abstract
90 Y-ibritumomab-tiuxetan (90 YIT) was used as a first-line therapy for patients with early-stage follicular lymphoma ( FL) or marginal zone B-cell lymphoma ( MZL). Thirty-one patients were treated, with an overall 3-month response rate of 100% (68% complete response, 29% unconfirmed complete response and 3% partial response). At a median follow-up of 56 months, ten patients (32%) had disease relapse or progression. The progression-free rates at 3 and 5 years were lower in males, patients with FL, stage II diseaseand non-bulky disease, although they did not reach statistical significance. Grade 3-4 neutropenia, thrombocytopenia and anaemia were 61%, 35%, and 3%, respectively.90 YIT was well tolerated, including in those patients over 60 years old, and achieved high response rates in patients with early-stage low-grade B-cell lymphomas. Bulky disease did not adversely affect tumour response. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
4. Prospective phase II study of rituximab with alternating cycles of hyper- CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.
- Author
-
Oki, Yasuhiro, Westin, Jason R., Vega, Francisco, Chuang, Hubert, Fowler, Nathan, Neelapu, Sattva, Hagemeister, Fredrick B., McLaughlin, Peter, Kwak, Larry W., Romaguera, Jorge E., Fanale, Michelle, Younes, Anas, Rodriguez, Maria Alma, Orlowski, Robert Z., Wang, Michael, Ouzounian, Souzanne T., Samaniego, Felipe, and Fayad, Luis
- Subjects
LYMPHOMA treatment ,B cell lymphoma ,CLINICAL trials ,RITUXIMAB ,DOXORUBICIN ,DEXAMETHASONE ,CANCER chemotherapy ,CYTARABINE ,METHOTREXATE ,TUMOR treatment - Abstract
We conducted a prospective randomized phase II study to evaluate two chemotherapy regimens: (i) rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone ( R- HCVAD) alternating with rituximab, high-dose methotrexate, and cytarabine ( R- MA) and (ii) rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone ( R- CHOP) in diffuse large B-cell lymphoma ( DLBCL). This study randomized patients aged ≤60 years with DLBCL and an age-adjusted international prognostic index ≥2 to R- HCVAD/ R- MA or R- CHOP based on a Bayesian adaptive algorithm. Interim analysis of the first 26 eligible patients showed that the complete response rate ( CRR) was higher with R- HCVAD/ R- MA than R- CHOP ( P = 0·03); thus, R- CHOP arm was closed. In the final analysis, 49 and 10 eligible patients were treated in R- HCVAD/ R- MA and R- CHOP arms respectively; CRR were 82% and 60% respectively ( P = 0·13); 3-year progression-free survival ( PFS) rates were 75·7% and 77·8% respectively ( P = 0·53). In the R- HCVAD/ R- MA arm, 3-year PFS rates in patients aged 46-60 years and ≤45 years were 70·3% and 87·1% respectively ( P = 0·13), and the treatment-associated early mortality rate in patients >45 years was 12%. In conclusion, R- HCVAD/ R- MA is associated with excellent outcome in patients ≤45 years old. However, in patients >45 years old, R- HCVAD/ R- MA is associated with unacceptable mortality rates. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
5. Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera
- Author
-
Cha, Soung-Chul, Kwak, Larry W., Ruffini, Pier Adelchi, Qin, Hong, Neelapu, Sattva, and Biragyn, Arya
- Subjects
- *
ANTIGENS , *CHROMATOGRAPHIC analysis , *GENETIC engineering , *IMMUNOGLOBULINS - Abstract
Abstract: Active immunization of follicular lymphoma patients with idiotypic vaccines elicits antigen-specific antibody responses, T-cell responses, and antitumor effects. We hypothesized that these vaccinated patients could generate tumor-specific immune responses, not only against idiotype, but also against other tumor-associated antigens (TAA) by a mechanism of epitope spreading. To identify potential antigens, a phage surface expressed cDNA library derived from primary tumor cells was screened with sera from idiotype-vaccinated patients. Consistent with our hypothesis, we identified two immunogenic peptides (FL-aa-7 and 18), unrelated to idiotype, which were recognized by postvaccine sera but not by prevaccine or normal human sera. These peptide sequences derived from the 5′-untranslated regions of the human GTPase, IMAP family member 7 gene (FL-aa-7) and an alternative reading frame of U1-snRNP 70 (FL-aa-18), respectively, suggesting that epitope spreading had occurred. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
6. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.
- Author
-
Neelapu, Sattva S., Kwak, Larry W., Kobrin, Carol B., Reynolds, Craig W., Janik, John E., Dunleavy, Kieron, White, Therese, Harvey, Linda, Pennington, Robin, Stetler-Stevenson, Maryalice, Jaffe, Elaine S., Steinberg, Seth M., Gress, Ronald, Hakim, Fran, and Wilson, Wyndham H.
- Subjects
- *
LYMPHOMAS , *RETICULOENDOTHELIAL granulomas , *B cell lymphoma , *CANCER vaccines , *B cells , *T cells , *IMMUNE response - Abstract
The role of B cells in T-cell priming is unclear, and the effects of B-cell depletion on immune responses to cancer vaccines are unknown. Although results from some mouse models suggest that B cells may inhibit induction of T cell–dependent immunity by competing with antigen-presenting cells for antigens, skewing T helper response toward a T helper 2 profile and/or inducing T-cell tolerance, results from others suggest that B cells are necessary for priming as well as generation of T-cell memory. We assessed immune responses to a well-characterized idiotype vaccine in individuals with severe B-cell depletion but normal T cells after CD20-specific antibody–based chemotherapy of mantle cell lymphoma in first remission. Humoral antigen- and tumor-specific responses were detectable but delayed, and they correlated with peripheral blood B-cell recovery. In contrast, vigorous CD4+ and CD8+ antitumor type I T-cell cytokine responses were induced in most individuals in the absence of circulating B cells. Analysis of relapsing tumors showed no mutations or change in expression of target antigen to explain escape from therapy. These results show that severe B-cell depletion does not impair T-cell priming in humans. Based on these results, it is justifiable to administer vaccines in the setting of B-cell depletion; however, vaccine boosts after B-cell recovery may be necessary for optimal humoral responses. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
7. Targeting B-cell malignancies through human B-cell receptor specific CD4 T cells.
- Author
-
Weng, Jinsheng, Baio, Flavio Egidio, Moriarty, Kelsey E., Torikai, Hiroki, Wang, Hua, Liu, Zhiqiang, Maiti, Sourindra N., Gwak, Dongho, Popescu, Michael S., Cha, Soung-Chul, Cooper, Laurence J. N., Neelapu, Sattva S., and Kwak, Larry W.
- Subjects
B cell lymphoma ,B cell receptors ,CD4 antigen ,TUMOR treatment - Abstract
The B-cell receptor (BCR) expressed by a clonal B cell tumor is a tumor specific antigen (idiotype). However, the T-cell epitopes within human BCRs which stimulate protective immunity still lack detailed characterization. In this study, we identified 17 BCR peptide-specific CD4+T-cell epitopes derived from BCR heavy and light chain variable region sequences. Detailed analysis revealed these CD4+T-cell epitopes stimulated normal donors' and patients' Th1 CD4+T cells to directly recognize the autologous tumors by secretion of IFNγ, indicating the epitopes are processed and presented by tumor cells. One BCR peptide-specific CD4+T cell line was also cytotoxic and lysed autologous tumor cells through the perforin pathway. Sequence analysis of the epitopes revealed that 10 were shared by multiple primary patients' tumors, and 16 had the capacity to bind to more than one HLA DRB1 allele. T cells stimulated by shared epitopes recognized primary tumors expressing the same sequences on multiple HLA DRB1 alleles. In conclusion, we identified 17 BCR-derived CD4+T-cell epitopes with promiscuous HLA DRB1 binding affinity that are shared by up to 36% of patients, suggesting a strategy to overcome the requirement for individual preparation of therapeutic agents targeting idiotype. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma.
- Author
-
Pradhan, Pallab, Qin, Hong, Leleux, Jardin A., Gwak, Dongho, Sakamaki, Ippei, Kwak, Larry W., and Roy, Krishnendu
- Subjects
- *
CANCER immunotherapy , *SMALL interfering RNA , *OLIGONUCLEOTIDES , *CYTOKINES , *ANTINEOPLASTIC agents , *T cells , *CANCER cells , *B cell lymphoma , *DENDRITIC cells - Abstract
Abstract: Success of an immunotherapy for cancer often depends on the critical balance of T helper 1 (Th1) and T helper 2 (Th2) responses driven by antigen presenting cells, specifically dendritic cells (DCs). Th1-driven cytotoxic T cell (CTL) responses are key to eliminating tumor cells. It is well established that CpG oligonucleotides (ODN), a widely studied Toll-like receptor 9 (TLR9) agonist, used to enhance Th1 response, also induces high levels of the anti-inflammatory, Th2-promoting cytokine IL10, which could dampen the resulting Th1 response. Biomaterials-based immunomodulatory strategies that can reduce IL10 production while maintaining IL12 levels during CpG delivery could further enhance the Th1/Th2 cytokine balance and improve anti-tumor immune response. Here we report that dual-delivery of IL10-silencing siRNA along with CpG ODN to the same DCs using pathogen-mimicking microparticles (PMPs), significantly enhances their Th1/Th2 cytokine ratio through concurrent inhibition of CpG-induced IL10 production. Co-delivery of poly(I:C), a TLR3 agonist had only minor effects on IL10 levels. Further, simultaneous immunotherapy with CpG ODN and IL10 siRNA enhanced immune protection of an idiotype DNA vaccine in a prophylactic murine model of B cell lymphoma whereas co-delivery of poly(I:C) and CpG did not enhance protection. These results suggest that PMPs can be used to precisely modulate TLR ligand-mediated immune-stimulation in DCs, through co-delivery of cytokine-silencing siRNAs and thereby boost antitumor immunity. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
9. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.
- Author
-
Weng, Jinsheng, Rawal, Seema, Chu, Fuliang, Jun Park, Hyun, Sharma, Rakesh, Delgado, David A., Fayad, Luis, Fanale, Michelle, Romaguera, Jorge, Luong, Amber, Kwak, Larry W., and Neelapu, Sattva S.
- Subjects
- *
ANTIGENS , *B cell lymphoma , *CANCER immunotherapy , *ANTI-idiotypic vaccines , *GENETIC code , *MESSENGER RNA - Abstract
Immunotherapy with therapeutic idiotype vaccines offers promise for treatment of B-cell malignancies. However, identifica-tion of novel immunogenic lymphoma-associated antigens that are universally expressed is necessary to overcome the barriers of patient-specific idiotype vac-cines. Here, we determined whether T-cell leukemia/lymphoma 1 (TCL1) oncopro-tein encoded by the TCL1 gene could be a target for immunotherapy of B-cell malig-nancies. We show that TCL1 mRNA and protein are selectively expressed in normal B cells but markedly hyperexpressed in multiple human B-cell lymphomas, in-cluding follicular lymphoma, chronic lym-phocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and splenic marginal zone B-cell lymphoma. We dem-onstrated that TCL1-specific CD8+ T cells can be generated from HLA-A*0201 (HLA-A2)+ normal donors and identified TCLI71-78 (LLPIMWQL) as the minimal epitope recognized by these T cells. More importantly, TCL171-78 peptide-specific T cells were present In the peripheral blood and tumor-infiltrating lymphocytes of lymphoma patients, could be expanded in vitro, and lysed autologous tumor cells but not normal B cells in an HLA-A2-restricted manner. Our results suggest thatTCLI is naturally processed and pre-sented on the surface of lymphoma cells for recognition by cytotoxic T cells and can serve as a novel target for develop-ment of immunotherapeutic strategies against common B-cell lymphomas. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
10. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma
- Author
-
Singh, Ankur, Qin, Hong, Fernandez, Irina, Wei, Jinsong, Lin, Jian, Kwak, Larry W., and Roy, Krishnendu
- Subjects
- *
B cell lymphoma , *T cells , *IMMUNOTHERAPY , *SMALL interfering RNA , *CANCER vaccines , *COLLOIDS in medicine , *LYMPHOMA treatment - Abstract
Abstract: Patients with malignant non-Hodgkin''s lymphomas (NHL) of B-cell lineages relapse despite initial anti-tumor response to chemotherapy or antibody treatments. Failure to eliminate the tumor is often because of inadequate priming, low cell numbers and suboptimal phenotype of effector T cells. Here we describe a new biomaterial-based controlled-release paradigm to treat weakly immunogenic NHLs by in-situ amplifying the number of functional, antigen-specific T-helper 1 (Th1) cells following immunotherapy. An injectable, synthetic immune priming center (sIPC) consisting of an in-situ crosslinking, chemokine-carrying hydrogel and both DNA- and siRNA dual-loaded microparticles, is reported. This sIPC chemo attracts a large number of immature dendritic cells (DCs) at the site of administration and efficiently co-delivers both DNA antigens and interleukin-10 (IL10)-silencing siRNA to those cells. Using a murine model of A20 B cell lymphoma, we demonstrate that combination of DNA-antigen delivery and IL10 silencing, synergistically activate recruited immature DCs and cause a strong shift towards Th1 response while suppressing Th2 and Th17 cytokines. sIPC-based immunotherapy showed 45% more CD8+ cytotoxic T cell (CTL) response and 53% stronger CD4+ CTL activity compared to naked DNA vaccine. In addition, in-vivo sIPC immunization induced significant protection (p <0.01) against subsequent tumor challenge. Such a multi-modal, injectable system that simultaneously delivers chemokines, siRNA and DNA antigens to DCs marks a new approach to in-situ priming and modulation during immunotherapy and could provide effective vaccination strategies against cancers and infectious diseases. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.